← Leaderboards
Brian Tsuji
State University Of New York At Buffalo
$5,737,626
Attributed
$11,475,252
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2014–25$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,475,252 · 3
By mechanism
R01$11,475,252 · 3
Top collaborators
- Jurgen Bernd Bulitta5 shared
- Jian Li5 shared
- Mark D. Sutton4 shared
Most similar at State University Of New York At Buffalo
Same institution · by research overlap
- Jurgen Bernd Bulitta$13,249,415
- Yanan Zhao$1,596,741
Others in their field
Top investigators on “Combat”
- Thomas William Geisbert · Boston University Medical Campus$53,901,766
- Alan A Aderem · University Of Washington$34,302,157
- Alpha Albert Lee · Sloan-Kettering Inst Can Research$33,555,942
- John Damon Chodera · Sloan-Kettering Inst Can Research$33,555,942
- Howard Fishbein · Battelle Centers/Pub Hlth Res & Evaluatn$29,828,069
- Jenny P.y. Ting · Univ Of North Carolina Chapel Hill$25,952,988
Research focus
CombatPathogenInsightIn VitroAntibioticsPharmaceutical PreparationsGenomicsResistanceFiberFutureRegimenBacteriaResistance MechanismAztreonamInnovationCombined AntibioticsInfectionMedicalDrug KineticsBeta-LactamsBeta-LactamaseClinicCarbapenemsClinical Trials
Grant awards (14)
Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa$757,308
R01 · FY2025 · AI · contact PI
Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa$768,514
R01 · FY2024 · AI · contact PI
Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs$751,348
R01 · FY2024 · AI · contact PI
Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa$775,929
R01 · FY2023 · AI · contact PI
Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs$764,100
R01 · FY2023 · AI · contact PI
Novel Combination Therapies to Combat Hypermutable Carbapenem-Resistant P. aeruginosa$805,095
R01 · FY2022 · AI · contact PI
Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs$783,756
R01 · FY2022 · AI · contact PI
Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs$782,154
R01 · FY2021 · AI · contact PI
Novel Strategies for Antibiotic Combinations to Combat Gram-negative Superbugs$839,004
R01 · FY2020 · AI · contact PI
Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative Superbugs$934,289
R01 · FY2018 · AI · contact PI
Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative Superbugs$857,287
R01 · FY2017 · AI · contact PI
Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative Superbugs$928,854
R01 · FY2016 · AI · contact PI
Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative Superbugs$902,595
R01 · FY2015 · AI · contact PI
Novel PK/PD Strategies for Polymyxin Combinations against Gram-negative Superbugs$825,019
R01 · FY2014 · AI · contact PI